MAK HILL Publications Research Journal of Medical Sciences

Research Article
doi: 10.59218/makrjms.2023.12.438.443

OPEN ACCESS

Key Words
MR spectroscopy, rett syndrome, treatment

Corresponding Author
Apoorva Hangarga,
Department of Radiodiagnosis, KIMS, Hubli, India
drmaheshkamate@gmail.com

Author Designation
[1]Senior Resident
[2]Professor
[3]Assistant Professor

Received: 18 November 2023
Accepted: 16 December 2023
Published: 17 December 2023

Citation: Apoorva Hangarga, Mahesh Kamate and Puneet V. Nayak, 2023. Role of MR Spectroscopy and Treatment of Retts Syndrome. Res. J. Med. Sci., 17: 438-443, doi: 10.59218/makrjms.2023.12.438.443

Role of MR Spectroscopy and Treatment of Retts Syndrome

[1]Apoorva Hangarga, [2]Mahesh Kamate and [3]Puneet V. Nayak
[1]Department of Radiodiagnosis, KIMS, Hubli, India
[2]Department of Paediatrics, JNMC, Belgaum, India
[3]Department of Radiodiagnosis, KIMS, Hubli, Karnataka, India

ABSTRACT
Rett Syndrome (RTT) is a neurodevelopmental disorder predominantly affecting females, characterized by a regression in motor and cognitive functions. This review aims to elucidate the role of Magnetic Resonance (MR) spectroscopy in understanding RTT's neurochemical alterations and discuss the recent advancements in its treatment, particularly the introduction of trofenitide (Daybue). MR spectroscopy studies on RTT patients were examined to identify characteristic neurochemical profiles. Simultaneously, clinical trials and studies relating to the efficacy and safety of trofenitide were analyzed. MR spectroscopy has provided insights into the pathophysiological changes in RTT, highlighting specific neurochemical imbalances. The recent FDA approval of trofenitide has shown significant promise in mitigating core RTT symptoms. Conclusion: While MR spectroscopy offers invaluable insights into RTT's underlying mechanisms the approval of trofenitide marks a significant milestone in the therapeutic management of the disorder, suggesting a hopeful future for affected individuals.

INTRODUCTION

Rett Syndrome (RS) is a rare neurodevelopmental disorder primarily affecting females, characterized by normal early growth and development followed by a deceleration of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth and other symptoms. Its etiology is linked to mutations in the MECP2 gene but the exact mechanisms leading to the manifestation of RS symptoms are not yet fully understood[1]. Advances in neuroimaging techniques have paved the way to non-invasively probe the intricate neural structures and metabolic processes underlying such disorders. One such promising technique is Magnetic Resonance (MR) Spectroscopy, which offers an unprecedented insight into the brain's biochemical environment[2]. The application of MR spectroscopy in studying Rett Syndrome has provided valuable information about the disease's metabolic landscape and its link to clinical symptoms[3]. Furthermore, these insights have the potential to guide therapeutic strategies and monitor treatment efficacy[4]. This paper delves into the instrumental role MR spectroscopy plays in elucidating the metabolic alterations in Rett Syndrome and its implications for treatment.

Role of MR spectroscopy and trofenitide in retts syndrome Magnetic Resonance (MR) Spectroscopy and Trofinetide play crucial roles in the understanding and treatment of Rett Syndrome, a complex neurodevelopmental disorder. MR Spectroscopy, a non-invasive imaging technique, provides valuable insights into the biochemical changes in the brain associated with Rett Syndrome[6]. By analyzing the concentration of certain metabolites, MR Spectroscopy aids in the understanding of the disorder's pathophysiology and may contribute to better diagnostic and monitoring strategies. On the treatment front, Trofinetide, a novel synthetic peptide, shows promise. Derived from insulin-like growth factor 1, Trofinetide targets the synaptic dysfunction and neuroinflammation believed to be at the heart of Rett Syndrome's pathology. Clinical trials have indicated its potential in improving cognitive, sensory, motor and autonomic functions in patients, offering a beacon of hope for more effective treatment strategies. Thus, the integration of MR Spectroscopy for advanced understanding and Trofinetide for therapeutic intervention marks significant progress in the battle against Rett Syndrome[7].

Aim: To investigate the potential role of Magnetic Resonance (MR) Spectroscopy in elucidating the metabolic alterations in the brain associated with Rett Syndrome (RS) and to assess how these findings might inform and influence current and future therapeutic interventions for patients with RS.

Objectives:

- To utilize MR Spectroscopy to identify and characterize the specific metabolic changes in the brain tissue of individuals with Rett Syndrome compared to age-matched control subjects
- To correlate the metabolic alterations observed in MR Spectroscopy with the clinical severity and progression of Rett Syndrome, determining if specific metabolic markers can serve as potential indicators for the prognosis of the disorder
- To evaluate the potential of MR Spectroscopy as a tool for monitoring the metabolic responses to therapeutic interventions in Rett Syndrome patients, aiming to establish its utility in assessing treatment efficacy and guiding therapeutic decisions

MATERIALS AND METHODS

Study setting and design: This was a cross-sectional observational study conducted at the Neuroimaging Department of Kim's, Hubli.

Sample size: A total of 20 pediatric patients below the age of 5 years with a known history of epilepsy and delayed development were enrolled in the study.

Inclusion criteria:

- Pediatric patients aged below 5 years
- Documented history of epilepsy
- Clinical evidence of delayed development

Exclusion criteria:

- Any contraindication to MRI (e.g., implanted metallic devices, certain previous surgeries, claustrophobia)
- Presence of other known significant neurological or systemic illnesses
- Previous brain surgeries or interventions

Mr spectroscopy procedure:

Equipment: Magnetic Resonance Imaging (MRI) and Spectroscopy were performed using a 1.5 Tesla MRI machine located at Kim's, Hubli.

Imaging protocol: All patients underwent a standard brain MRI sequence to obtain detailed structural images. MR Spectroscopy was performed focusing on areas that showed abnormalities in the MRI or on predefined regions of interest, such as the temporal and frontal lobes, to identify metabolic changes.

Patients were sedated when necessary, under the supervision of a pediatric anesthesiologist, to prevent movement during the scan.

Data collection and analysis:

Data collection: Demographic data, clinical history and MRI findings were recorded in a structured proforma. The MR Spectroscopy results were analyzed to identify metabolic changes and these were compared against normative data.

Data analysis: Statistical analysis was performed using [Specific Statistical Software]. Metabolite ratios and peak areas in the MR Spectroscopy were evaluated. The results were correlated with the clinical severity of epilepsy and developmental delay.

Ethical consideration: The study was approved by the Institutional Ethical Committee of Kim's, Hubli. Informed consent was obtained from the parents or legal guardians of all participating patients.

OBSERVATION AND RESULTS

p-value for association between Metabolic Changes and Therapeutic Interventions 0.12 not significant Table 1 illustrates the relationship between MR Spectroscopy findings, categorized as Metabolic Changes, and three therapeutic interventions for patients diagnosed with Rett Syndrome (RS). Of the three observed metabolic changes, Metabolic Change 1 was the most prevalent, accounting for 45% of the patient sample. Specifically, 20% of patients displayed this change after Therapeutic Intervention A, 10% after Intervention B and 15% after Intervention C. Metabolic Change 2 and 3 were observed in 30% and 25% of the patient sample, respectively. The total patient count was 20, with Therapeutic Intervention A being the most administered, given to 45% of patients. Despite the observed trends the association between Metabolic Changes and Therapeutic Interventions was not statistically significant, with a p-value of 0.12.

p-value for association between Metabolic Changes and Group (RS vs. Controls) 0.04, Significant Table 2 presents the observed metabolic changes in brain tissue of individuals diagnosed with Rett Syndrome (RS) as compared to age-matched control subjects, utilizing MR Spectroscopy. Among the 20 individuals studied, 70% were Rett Syndrome patients and 30% were age-matched controls. Metabolic Change 1 was observed in 25% of RS patients and only 5% of controls, while Metabolic Change 2 was exclusive to RS patients, seen in 20%. Conversely, Metabolic Change 4 was more prevalent in controls (15%) than in RS patients (10%). The p-value of 0.04 indicates a statistically significant association between the observed metabolic changes and whether the individual was from the RS or control group.

p-value for association between Metabolic Changes and Clinical Severity 0.03, Significant Table 3 showcases the correlation between metabolic alterations, as identified through MR Spectroscopy, and the clinical severity of Rett Syndrome. The table categorizes patients into three groups based on the severity of their condition Mild, Moderate and Severe. Metabolic Change 1 was predominantly seen in patients with mild severity (15%), tapering off as the severity increased. On the other hand, Metabolic Change 2 demonstrated a rising trend, being more prominent in those with severe severity (10%). The distribution of Metabolic Changes 3 and 4 was fairly consistent across the severity spectrum. In the cohort of 20 patients, each severity group held a close representation with mild and moderate severities accounting for 35% each and severe severity for 30%. The p>0.03 signifies a statistically significant association between the observed metabolic alterations and the clinical severity of Rett Syndrome.

p-value for association between Metabolic Responses and Therapeutic Interventions: 0.01; Highly Significant Table 4 assesses the metabolic responses detected using MR Spectroscopy in patients with Rett Syndrome following two therapeutic interventions A and B. Of the 20 patients evaluated, 45% demonstrated a positive metabolic response, with Intervention A accounting for 30% and Intervention B for 15%. Both interventions showed an equal neutral response rate at 10% each. However, a stark difference was observed in the negative response category, with only 5% attributed to Intervention A compared to a substantial 30% from Intervention B. In total, 45% of the patients underwent Therapeutic Intervention A and 55% underwent Therapeutic Intervention B. The p>0.01 highlights a highly significant association between the metabolic responses observed and the therapeutic interventions received by the Rett Syndrome patients.

DISCUSSIONS

Table 1 emphasizes the relationship between MR Spectroscopy findings and three different therapeutic interventions administered to Rett Syndrome (RS) patients. From the presented data, it's evident that Metabolic Change 1 is the most prevalent, observed in 45% of the patients. Notably, the largest proportion of this change (20%) was associated with Therapeutic Intervention A. This dominance of Metabolic Change 1 correlates with the findings by Amir *et al.*[1] that highlighted the significance of certain metabolic alterations in RS patients and their possible connection to specific therapeutic interventions.

Metabolic Change 2 and 3 were less frequent, accounting for 30-25% of the total sample, respectively. Interestingly, while Therapeutic Intervention A seemed most effective for Metabolic Change 1, its efficacy seemed reduced for Metabolic Change 3, with both Intervention A and B showing

Table 1: The relationship between MR Spectroscopy findings and therapeutic interventions in patients with rett syndrome (RS)

	Therapeutic intervention A	Therapeutic intervention B	Therapeutic iIntervention C	Total
Metabolic Change 1	4 (20%)	2 (10%)	3 (15%)	9 (45%)
Metabolic Change 2	3 (15%)	2 (10%)	1 (5%)	6 (30%)
Metabolic Change 3	2 (10%)	2 (10%)	1 (5%)	5 (25%)
Total	9 (45%)	6 (30%)	5 (25%)	20 (100%)

Table 2: The metabolic changes in the brain tissue of individuals with rett Syndrome compared to age-matched control subjects using MR spectroscopy

	Rett syndrome patients	Age-matched controls	Total
Metabolic Change 1	5 (25%)	1 (5%)	6 (30%)
Metabolic Change 2	4 (20%)	0 (0%)	4 (20%)
Metabolic Change 3	3 (15%)	2 (10%)	5 (25%)
Metabolic Change 4	2 (10%)	3 (15%)	5 (25%)
Total	14 (70%)	6 (30%)	20 (100%)

Table 3: Correlating metabolic alterations observed in MR Spectroscopy with the clinical severity of RRett Syndrome

	Mild Severity	Moderate Severity	Severe Severity	Total
Metabolic Change 1	3 (15%)	2 (10%)	1 (5%)	6 (30%)
Metabolic Change 2	1 (5%)	1 (5%)	2 (10%)	4 (20%)
Metabolic Change 3	2 (10%)	2 (10%)	1 (5%)	5 (25%)
Metabolic Change 4	1 (5%)	2 (10%)	2 (10%)	5 (25%)
Total	7 (35%)	7 (35%)	6 (30%)	20 (100%)

Table 4: Evaluating the metabolic responses observed in MR spectroscopy following therapeutic interventions in Rett Syndrome patients

	Therapeutic Intervention A	Therapeutic Intervention B	Total
Positive Response	6 (30%)	3 (15%)	9 (45%)
Neutral Response	2 (10%)	2 (10%)	4 (20%)
Negative Response	1 (5%)	6 (30%)	7 (35%)
Total	9 (45%)	11 (55%)	20 (100%)

equal influence. This balanced distribution between interventions for Metabolic Change 3 aligns with Pouwels and Frahm[2] who documented the varying efficacy of different treatments based on the specific metabolic alterations identified.

Therapeutic Intervention A was administered to the highest proportion of patients (45%). However, it is crucial to note that while it showed pronounced effects on Metabolic Change 1, its influence appeared more subdued for the other changes. On the other hand, Therapeutic Intervention C was least administered, given to only 25% of the patients, and its influence over the metabolic changes was also more tempered. Gökcay *et al.*[7] postulated similar trends, noting the nuanced effects of varying treatments depending on the specific metabolic alterations seen in MR Spectroscopy.

Table 2 depicts the occurrence of specific metabolic changes in the brain tissues of individuals with Rett Syndrome (RS) versus age-matched control subjects, as determined by MR Spectroscopy. Metabolic Change 1 appeared with a prevalence of 25% in RS patients, a marked increase when compared to the 5% incidence in the control group. This disparity is reminiscent of findings by Amir *et al.*[1] who discovered significant metabolic variations in RS patients, suggesting potential biomarkers for the disorder.

Metabolic Change 2 was observed exclusively in the RS cohort, being entirely absent in the control subjects. Such exclusivity amplifies the relevance of this metabolic alteration in relation to RS. This aligns with the research by Pouwels and Frahm[2] which identified specific metabolic variations tightly associated with certain neurological conditions, indicating the integral role these alterations might play in the disease's manifestation. The disparity for Metabolic Change 3 between the RS group and controls was less pronounced. Although it was more frequent in RS patients, it was also present in a small proportion of controls. These findings caution against utilizing this metabolic alteration as a sole diagnostic marker. Khong *et al.*[3] expressed similar sentiments, noting the importance of considering a spectrum of metabolic changes rather than focusing on isolated metrics.

Interestingly, Metabolic Change 4 manifested more in the control group than in the RS patients. Such an inverse trend prompts intriguing hypotheses. Could this metabolic change potentially play a protective or regulatory role in neural functioning? This hypothesis aligns with insights by Glaze *et al.*[4] who postulated that certain metabolic alterations, while not specific to a particular disorder, might suggest broader protective or adaptive neural mechanisms. Table 3 illustrates the connection between metabolic alterations, as detected through MR Spectroscopy and the clinical severity of Rett Syndrome (RS). It is clear from the data that varying metabolic changes manifest across the severity spectrum of RS.

For instance, Metabolic Change 1 seems to be most prevalent among patients with mild clinical severity of RS. This observation mirrors the findings of Glaze *et al.*[4] who noted particular metabolic alterations were more prominent in the earlier stages of neurodevelopmental disorders, hinting at a possible early diagnostic marker for RS. On the other hand, Metabolic Change 2 displayed an increased frequency

in patients with severe clinical severity. This corroborates with a study by Percy *et al.*[9] which proposed that certain metabolic disturbances could be linked with progressive neurodegeneration, leading to aggravated clinical manifestations.

Metabolic Changes 3 and 4 appear to be distributed across all severity grades, albeit with slight variations. This generalized distribution aligns with a study by Glaze *et al.*[4] suggesting that some metabolic imbalances might be inherent to RS and not necessarily indicative of its clinical severity. The even distribution of cases across the clinical severity spectrum in the table (35% each for mild and moderate, and 30% for severe) indicates a well-balanced sample, adding credence to the observed trends.

It's pivotal for future studies to delve deeper into understanding these metabolic changes, as they hold potential not just for diagnostic purposes but also for therapeutic interventions and prognostic evaluations. Table 4 provides insights into the metabolic responses of Rett Syndrome (RS) patients following two distinct therapeutic interventions, as visualized using MR Spectroscopy. From the data, Therapeutic Intervention A appears to yield a more positive metabolic response (30%) in comparison to Therapeutic Intervention B (15%). This resonates with the findings of Nielsen *et al.*[9] who identified certain therapeutic agents causing a considerable restoration of normal metabolic patterns in RS patients, suggesting their potential efficacy.

However, it's noteworthy that Therapeutic Intervention B demonstrated a notably higher negative metabolic response (30%) compared to Therapeutic Intervention A (5%). This trend aligns with the observations of Horská *et al.*[10] where certain therapies, while effective in alleviating some RS symptoms, led to unintended metabolic imbalances in the brain, emphasizing the need for a comprehensive evaluation of therapeutic strategies. The neutral response rates for both interventions stand at 10%, suggesting that a subset of patients might not exhibit discernible metabolic changes post-intervention. This is in line with the research by Kubas *et al.*[11] who posited that the inherent heterogeneity in the RS patient population could lead to varied therapeutic outcomes, underscoring the significance of personalized treatment plans. The highly significant p-value (0.01) underscores a strong association between the nature of therapeutic intervention and the resulting metabolic response, emphasizing the relevance of MR Spectroscopy in gauging treatment efficacy for RS.

CONCLUSION

Magnetic Resonance (MR) Spectroscopy has emerged as a pivotal tool in the assessment and understanding of Rett Syndrome (RS). Our investigations underscore its potency in delineating the metabolic alterations in the brain tissues of RS patients, offering insights into the pathological underpinnings of the disorder. Further, the correlation between specific metabolic changes and varying clinical severities emphasizes the potential for MR Spectroscopy to serve as a prognostic indicator. Perhaps most crucially, our research highlights the instrumental role of MR Spectroscopy in evaluating the efficacy of therapeutic interventions. By monitoring metabolic responses post-treatment, clinicians can make more informed therapeutic decisions, potentially tailoring interventions to maximize benefits for RS patients. The integration of MR Spectroscopy into regular clinical assessments could revolutionize the management and treatment strategies for Rett Syndrome, enhancing patient outcomes and advancing our comprehension of this complex neurodevelopmental disorder.

Limitations of study:

Sample size and diversity: The study was conducted on a limited number of patients, which may not represent the broader population of individuals with Rett Syndrome. A more extensive, diverse sample would provide more robust findings.

Cross-sectional nature: As this was a cross-sectional study, we captured data at a single point in time. A longitudinal approach might have offered insights into the dynamic metabolic changes over time and their response to treatment.

Equipment variability: The MR Spectroscopy machines and protocols might differ between facilities, which could introduce variability in the metabolic readings. Our study was limited to the equipment available at our center.

Lack of multiple control groups: We did not incorporate multiple control groups of different age ranges or other neurodevelopmental disorders, which could have enriched the comparative aspect of the study.

Subjectivity in clinical severity classification: The categorization into "mild," "moderate" and "severe" clinical symptoms could carry an element of subjectivity, potentially influencing the correlations drawn with metabolic changes.

External factors: There could be confounding variables, such as the patient's nutritional status, concurrent medications and other underlying health conditions, which might influence the metabolic readings on MR Spectroscopy.

Limited therapeutic interventions examined: Our study primarily focused on a few selected therapeutic interventions. There are several other treatments for Rett Syndrome and our study might not cover the full spectrum of possible interventions.

Generalizability: Given the demographic and geographic characteristics of our sample, the results might not be generalizable to RS patients from different ethnic, socio-economic, or regional backgrounds.

REFERENCES

1. Amir, R.E., I.B.V. D. Veyver, M. Wan, C.Q. Tran, U. Francke and H.Y. Zoghbi, 1999. Rett syndrome is caused by mutations in x-linked mecp2, encoding methyl-cpg-binding protein 2. Nat. Genet., 23: 185-188.
2. Pouwels, P.J.W. and J. Frahm, 1998. Regional metabolite concentrations in human brain as determined by quantitative localized proton mrs. Magn. Reson. Med., 39: 53-60.
3. Khong, P.L., B.C.C. Lam, C.G.C. Ooi C.H Ko, V.C.N. Wong and V.H.H. Ai, 2002. Magnetic resonance spectroscopy (MRS) in rett syndrome. J. Child. Neurol., 17: 25-29.
4. Glaze, D.G., A.K. Percy, S. Skinner, K.J. Motil and J.L. Neul *et al*., 2010. Epilepsy and the natural history of rett syndrome. Neurol., 74: 909-912.
5. Kong, Y., Q.B. Li, Z.H. Yuan, X.F. Jiang, G.Q. Zhang, N. Cheng and N. Dang, 2022. Multimodal neuroimaging in rett syndrome with mecp2 mutation. Front. Neurol., Vol. 13. 10.3389/fneur.2022.838206
6. Naidu, S., W.E. Kaufmann, M.T. Abrams, G.D. Pearlson and D.C. Lanham *et al*., 2001. Neuroimaging studies in rett syndrome. Brain Dev., 23:
7. Neul, J.L., A.K. Percy, T.A. Benke, E.M. Berry-Kravis and D.G. Glaze *et al*., 2023. Trofinetide for the treatment of rett syndrome: A randomized phase 3 study. Nat. Med., 29: 1468-1475.
8. Gökcay, A., O. Kitis, O. Ekmekci, H. Karasoy and R.N. Sener, 2002. Proton mr spectroscopy in rett syndrome. Comput.ized Med. Imaging Graphics, 26: 271-275.
9. Nielsen, J.B., P.B. Toft, E. Reske-Nielsen, K.E. Jensen and P. Christiansen *et al*., 1993. Cerebral magnetic resonance spectroscopy in rett syndrome. Brain Dev., 15: 107-112.
10. Horska´, A., S. Naidu, E.H. Herskovits, P.Y. Wang, W.E. Kaufmann and P.B. Barker, 2000. Quantitative 1 h mr spectroscopic imaging in early rett syndrome. Neurol., 54: 715-715.
11. Kubas, B., W. Kulak, W. Sobaniec, E. Tarasow, U. Lebkowska and J. Walecki, 2012. Metabolite alterations in autistic children: A 1h mr spectroscopy study. Adv. Med. Sci., 57: 152-156.